Solifenacin Succinate Dry Compression Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The stability and dissolution profiles of solifenacin succinate in pharmaceutical compositions are compromised due to its strong aggregation properties and amorphous form, leading to poor content uniformity and chemical degradation, especially during direct compression and wet granulation processes.
Innovation Solution
A dry technological method involving direct compression or roller compaction is used to prepare solid oral dosage forms of solifenacin succinate without solvents, employing crystalline forms and specific excipients to maintain stability and bioavailability, avoiding the use of solvents and controlling process parameters to minimize amorphous fraction formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If direct compression method is used to prepare solifenacin succinate tablets, then manufacturing simplicity is improved, but content uniformity deteriorates due to strong aggregation properties
Solution Approach 1:
The patent changes the physical state parameter of solifenacin succinate from amorphous to crystalline form, and optimizes particle size parameters through size reduction. These parameter changes eliminate aggregation properties, enabling direct compression to achieve both manufacturing simplicity and content uniformity (RSD ≤ 6%)
Solution Approach 2:
The patent performs preliminary size reduction of solifenacin succinate crystals to obtain particles with diameter ≤ 200 μm before compression. This preliminary action prevents aggregation during the direct compression process, ensuring both ease of manufacture and content uniformity
2Productivity
If amorphous form of solifenacin succinate is used, then dissolution profile is improved, but chemical stability deteriorates leading to degradation
Solution Approach 1:
The patent changes the physical state parameter from amorphous to crystalline form, and optimizes particle size parameters. This resolves the contradiction by achieving both adequate dissolution (≥ 80% in 30 minutes) and chemical stability (degradation < 2% after 6 months at 40°C/75% RH)
Solution Approach 2:
The patent creates a composite system using crystalline solifenacin succinate particles (diameter ≤ 200 μm) combined with specific excipients including disintegrants (1-40 wt%), binders (1-50 wt%), and lubricants (0.1-10 wt%). This composite formulation achieves both dissolution and stability requirements
3Productivity
If high ratio of amorphous form is used to improve dissolution, then dissolution profile is improved, but stability deteriorates resulting in high degradation product formation
Solution Approach 1:
The patent fundamentally changes the physical state parameter from amorphous to crystalline form and optimizes particle size to ≤ 200 μm. This eliminates the harmful aggregation effect while maintaining dissolution (≥ 80% in 30 minutes) and minimizing degradation products (N-oxide formation < 2% after 6 months storage)
Solution Approach 2:
The patent converts the potential harm of crystalline form (slower dissolution than amorphous) into benefit by using size reduction (diameter ≤ 200 μm) and optimized excipient combinations. This achieves rapid dissolution ≥ 80% in 30 minutes while eliminating aggregation-related degradation, converting the potential disadvantage into a beneficial stable formulation
Data Source
AI summary
Pharmaceutical compositions comprising solifenacin or its pharmaceutically acceptable salts as the active pharmaceutical ingredient prepared by dry technological methods, preferably by the direct compression or roller compaction method, i.e. by the process in the absence of a liquid solvent, and the process for their preparation, are disclosed.